Complications of therapy for ANCA-associated vasculitis
- 1 May 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 59 (Supplement), 74-78
- https://doi.org/10.1093/rheumatology/kez618
Abstract
The introduction of immunosuppressive therapies has transformed ANCA-associated vasculitis (AAV) from a largely fatal condition to a chronic relapsing disorder. However, progressive organ damage and disability, both from the disease process itself and from therapies used for treatment, eventually affect the majority of patients. Infection, rather than uncontrolled vasculitis, is the greatest cause of early mortality and remains a major problem thereafter. Increased rates of malignancy and cardiovascular disease are additional important long term sequelae. This review focuses on the complications associated with the immunosuppressive therapies most commonly used to treat ANCA-associated vasculitis, and considers prophylactic and monitoring strategies to minimize these risks. Achieving a balance between immunosuppression to reduce relapse risk and minimizing the adverse effects associated with therapy has become key. The contribution of glucocorticoids to treatment toxicity is increasingly being recognized, and future therapeutic strategies must concentrate on glucocorticoid minimization or sparing strategies. Development of robust predictors of an individual's future clinical course is needed in order to individually tailor treatment regimens.Funding Information
- University of Cambridge
This publication has 36 references indexed in Scilit:
- Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trialsAnnals Of The Rheumatic Diseases, 2011
- EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseasesAnnals Of The Rheumatic Diseases, 2010
- Long-term patient survival in ANCA-associated vasculitisAnnals Of The Rheumatic Diseases, 2010
- Rituximab versus Cyclophosphamide for ANCA-Associated VasculitisThe New England Journal of Medicine, 2010
- Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical TrialsThe Journal of Rheumatology, 2010
- EULAR recommendations for the management of primary small and medium vessel vasculitisAnnals Of The Rheumatic Diseases, 2008
- Cancer incidence in a population‐based cohort of patients with Wegener's granulomatosisInternational Journal of Cancer, 2002
- Trimethoprim–Sulfamethoxazole (Co-Trimoxazole) for the Prevention of Relapses of Wegener's GranulomatosisThe New England Journal of Medicine, 1996
- Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide.Annals Of The Rheumatic Diseases, 1996
- Wegener Granulomatosis: An Analysis of 158 PatientsAnnals of Internal Medicine, 1992